Neurolief Ltd.

Neurolief Ltd. is Israel-based company specializing in innovative non-invasive neuromodulation therapies aimed at addressing Major Depressive Disorder (MDD) through advanced technology and data analytics. Founded in 2014 and headquartered in Israel Neurolief Ltd. focuses on developing non-invasive neuromodulation systems for mental health treatment.

The company has engaged in one significant funding deal as of August 2025, attracting investment from BrainsWay Ltd. Neurolief does not have any publicly known subsidiaries or a parent company, and there are no mentions of any business pivots or changes in operations since its inception. Neurolief's primary product is an innovative non-invasive neuromodulation system designed to treat Major Depressive Disorder (MDD). This technology employs three adaptive channels to deliver precise electrical pulses through neural pathways, stimulating neurotransmitter release and modulating mood-related brain networks.

The system includes a wearable unit, a patient-friendly mobile app, and cloud-based analytics, enabling therapy for patients who have not responded to traditional antidepressants. The company targets healthcare providers, mental health professionals, and directly affected patients, aiming for global expansion with anticipated regulatory approvals in the U. S. , Europe, and Japan.

Neurolief generates revenue through the sale of its neuromodulation devices and associated services to healthcare providers and institutions. The company conducts direct sales to medical facilities and partners with mental health clinics and hospitals, offering both procurement of the units and ongoing service agreements for software support. Specific pricing plans are not publicly disclosed as the technology remains under investigational status for MDD treatment. Neurolief has established credibility in the medical device market by securing FDA, CE, and PMDA approvals for its migraine treatment, which may enhance its marketability within the healthcare sector.

Neurolief plans to leverage recent funding received in October 2025 from BrainsWay Ltd. for the commercial launch of its ProlivRx system for major depressive disorder, pending FDA approval. This initiative aligns with the company's strategy to expand its product offerings and reach new markets, specifically targeting regions in the United States, Europe, and Japan for regulatory approvals. The funding will support the preparations necessary for this launch, enabling Neurolief to enhance its presence in the mental health treatment landscape.